# A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)

> **NCT07640789** · PHASE3 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 418 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage III

## Interventions

- **DRUG:** BL-B01D1
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT07640789
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-28
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 418 (ESTIMATED)
- **Last updated:** 2026-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640789, "A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*